Castration-Resistant Prostate Carcinoma

Oncology·MeSH: Prostatic Neoplasms

22 drugs in development·7 companies·19 clinical trials

Drug Pipeline by Phase

Phase 3(9)

Drug	Company
Abiraterone Acetate	ARS Pharmaceuticals, Inc. (SPRY)
Apalutamide	ARS Pharmaceuticals, Inc. (SPRY)
Cabazitaxel	KYNTRA BIO INC. (KYNB)
degarelix	KYNTRA BIO INC. (KYNB)
Goserelin acetate	KYNTRA BIO INC. (KYNB)
Leuprolide acetate	KYNTRA BIO INC. (KYNB)
New Formulation of Niraparib and Abiraterone Acetate	Royalty Pharma plc (RPRX)
New Formulation of Niraparib and Abiraterone Acetate	ARS Pharmaceuticals, Inc. (SPRY)
Rucaparib camsylate	KYNTRA BIO INC. (KYNB)

Phase 2(5)

Drug	Company
BET Bromodomain Inhibitor ZEN-3694	KYNTRA BIO INC. (KYNB)
Goserelin Acetate	Royalty Pharma plc (RPRX)
Leuprolide Acetate	Royalty Pharma plc (RPRX)
Lutetium Lu 177 Vipivotide Tetraxetan	KYNTRA BIO INC. (KYNB)
Valemetostat Tosylate	KYNTRA BIO INC. (KYNB)

Phase 1(7)

Drug	Company
Abiraterone acetate	Royalty Pharma plc (RPRX)
Anti-STEAP1 CAR T-cells	KYNTRA BIO INC. (KYNB)
Avelumab	Accustem Sciences Inc. (ACUT)
Enzalutamide	Filana Therapeutics Inc. (FLNA)
Fludarabine	KYNTRA BIO INC. (KYNB)
Testosterone Cypionate	Royalty Pharma plc (RPRX)
Testosterone Cypionate	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 4(1)

Drug	Company
Lutetium Lu 177 Vipivotide Tetraxetan	Novartis AG (NVS)

BioSniper tracks 22 drugs in development for Castration-Resistant Prostate Carcinoma across 7 companies.

There are 19 clinical trials targeting Castration-Resistant Prostate Carcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.